Company / Cost of Revenue
Celldex Therapeutics, Inc. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$200.0K
FY2025
5-year range
$100.0K / $300.0K
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
#113 of 113
Health Care
What the data says
Among 113 Health Care companies, Celldex Therapeutics, Inc. is in the top 0% for cost of revenue. Cost of Revenue has fluctuated over the past 10 years, ranging from $100,000 in FY2022 to $2M in FY2018.
Based on SEC 10-K filings.
$200,000 in FY2025 with a 5-year CAGR of +0.0%.
Improved from $300,000 to $200,000 over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +26.0%
- 5-Year CAGR
- +0.0%
- 10-Year CAGR
- -
Sector benchmark
Top 0% in Health CareTop 0% of 113This company $200.0K Sector average $11.3B
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.0%, indicating consistent growth.
- In FY2025, cost of revenue increased 0.0% year-over-year.
- Ranks #113 out of 113 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $200.0K | +0.0% |
| FY2024 | $200.0K | -33.3% |
| FY2023 | $300.0K | +200.0% |
| FY2022 | $100.0K | +0.0% |
| FY2021 | $100.0K | -50.0% |
| FY2020 | $200.0K | +100.0% |
| FY2019 | $100.0K | -93.8% |
| FY2018 | $1.6M | +128.6% |
| FY2017 | $700.0K | -56.3% |
| FY2016 | $1.6M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026